Aurinia Pharmaceuticals Inc (AUPH)

[zzaatt]

A bit of oversimplification of a complex situation. The single most important variable is the proven efficacy of Lupkynis, for a deadly disease, one for which there is no better treatment.

There were many headwinds for Aurinia (including Covid which made it just about impossible to promote the drug, not to mention the state of the economy and market).

It's a volatile situation, down one day, up the next! Aurinia is taking steps to move into a robust, self-sustaining state. They are not desperate to be bought immediately, which gives them a better bargaining position in the future.